Home >> Research Area >>Others>>Polo-like Kinase>> Cyclapolin 9

Cyclapolin 9

Selective, ATP-competitive PLK1 inhibitor CAS# 40533-25-3

Cyclapolin 9

Catalog No. BCC7571----Order now to get a substantial discount!

Product Name & Size Price Stock
Cyclapolin 9: 5mg $69 In Stock
Cyclapolin 9: 10mg Please Inquire In Stock
Cyclapolin 9: 20mg Please Inquire Please Inquire
Cyclapolin 9: 50mg Please Inquire Please Inquire
Cyclapolin 9: 100mg Please Inquire Please Inquire
Cyclapolin 9: 200mg Please Inquire Please Inquire
Cyclapolin 9: 500mg Please Inquire Please Inquire
Cyclapolin 9: 1000mg Please Inquire Please Inquire
Related Products
  • MLN8237 (Alisertib)

    Catalog No.:BCC2166
    CAS No.:1028486-01-2
  • SCH-1473759

    Catalog No.:BCC1934
    CAS No.:1094069-99-4
  • Reversine

    Catalog No.:BCC1892
    CAS No.:656820-32-5
  • AZD1152

    Catalog No.:BCC1393
    CAS No.:722543-31-9
  • XL228

    Catalog No.:BCC2058
    CAS No.:898280-07-4

Quality Control of Cyclapolin 9

Number of papers citing our products

Chemical structure

Cyclapolin 9

3D structure

Chemical Properties of Cyclapolin 9

Cas No. 40533-25-3 SDF Download SDF
PubChem ID 2779952 Appearance Powder
Formula C9H4F3N3O4S M.Wt 307.21
Type of Compound N/A Storage Desiccate at -20°C
Solubility Soluble to 25 mM in DMSO and to 10 mM in ethanol
Chemical Name 7-nitro-3-oxido-5-(trifluoromethyl)-1,3-benzothiazol-3-ium-2-carboxamide
SMILES C1=C(C=C(C2=C1[N+](=C(S2)C(=O)N)[O-])[N+](=O)[O-])C(F)(F)F
Standard InChIKey FHFLXKUKCSDMLD-UHFFFAOYSA-N
Standard InChI InChI=1S/C9H4F3N3O4S/c10-9(11,12)3-1-4-6(5(2-3)15(18)19)20-8(7(13)16)14(4)17/h1-2H,(H2,13,16)
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Biological Activity of Cyclapolin 9

DescriptionSelective, ATP-competitive polo-like kinase 1 (PLK1) inhibitor (IC50 = 500 nM).

Cyclapolin 9 Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

Cyclapolin 9 Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of Cyclapolin 9

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 3.2551 mL 16.2755 mL 32.551 mL 65.102 mL 81.3776 mL
5 mM 0.651 mL 3.2551 mL 6.5102 mL 13.0204 mL 16.2755 mL
10 mM 0.3255 mL 1.6276 mL 3.2551 mL 6.5102 mL 8.1378 mL
50 mM 0.0651 mL 0.3255 mL 0.651 mL 1.302 mL 1.6276 mL
100 mM 0.0326 mL 0.1628 mL 0.3255 mL 0.651 mL 0.8138 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University
Featured Products
New Products
 

References on Cyclapolin 9

Caspase 12 degrades IkappaBalpha protein and enhances MMP-9 expression in human nasopharyngeal carcinoma cell invasion.[Pubmed:28380444]

Oncotarget. 2017 May 16;8(20):33515-33526.

Caspase-12 (Casp12), an inflammatory caspase, functions as a dominant-negative regulator of inflammatory responses and is associated with the signaling of apoptosis. However, the physiological function of Casp12 presented in cancer cells is still unclear. This study demonstrated that overexpression of Casp12 mediated IkappaBalpha degradation and significantly increased NF-kappaB activity. Exposure of human nasopharyngeal carcinoma (NPC) cells to phorbol-12-myristate-13-acetate (PMA) increased the levels of Casp12 and MMP-9 resulting in NPC cell invasion. Target suppression of Casp12 by small interfering RNA (siRNA) or an inhibitor of Casp12 markedly decreased the level of PMA-induced MMP-9 protein and cell invasion. Moreover, suppression of Casp12 significantly inhibited the basal activity of NF-kappaB and decreased the PMA-induced NF-kappaB reporter activity. The effect of Casp12 on NF-kappaB activation was indicated via the post-translational degradation of IkappaB. This study revealed that a critical role of Casp12 on the activation of NF-kappaB via IkappaBalpha degradation which provides a link between inflammatory and aggressive invasion in NPC cells.

Growth performance of immunologically castrated pigs slaughtered at 5, 7, or 9 weeks after the second Improvest dose and fed diets containing corn dried distillers grains with solubles.[Pubmed:28380585]

J Anim Sci. 2017 Feb;95(2):806-819.

Growth performance of immunologically castrated (IC) pigs (863 total) was determined at increasing time intervals between the second Improvest (gonadotropin releasing factor analog-diphtheria toxoid conjugate; Zoetis Inc., Florham Park, NJ) dose and slaughter (TD) and with 4 different dried distillers grains with solubles (DDGS) feeding strategies (FS) in a 4 x 3 factorial arrangement of treatments. The feeding period was divided into 4 separate diet phases. Dietary treatments included 1) corn-soybean meal control diets (PCon), 2) a gradual decrease of dietary DDGS inclusion rate from 40%, 30%, 20%, and 10% in phases 1 to 4 (GD), respectively, 3) feeding 40% DDGS diets in phases 1 to 3 and removal of DDGS from the phase 4 diet (WD), and 4) feeding 40% DDGS diets in all 4 phases (NCon). Pigs received the second Improvest dose at 9 (TD9), 7 (TD7), or 5 (TD5) wk before slaughter. In each group, all pigs were slaughtered on the same day. There were no 3-way interactions among FS, TD, and week of feeding period for any measure of growth performance. Pigs fed PCon and WD had greater ( < 0.05) overall ADFI than pigs fed NCon, especially when slaughtered 9 wk after the second Improvest dose (2.45 and 2.44 vs. 2.31 +/- 0.08 kg/d, respectively). This response was partly due to withdrawing DDGS from the diet at 19 wk of age (WD), which led to a tendency ( < 0.10) for increased ADFI from the wk 19 to 21 interval to the wk 21 to 24 interval (3.26 vs. 3.51 +/- 0.09 kg/d, respectively). During the same time period, ADFI was unchanged ( > 0.05) in pigs fed PCon, GD, and NCon. Overall G:F was improved ( < 0.05) in TD5 pigs compared with TD9 pigs and tended ( < 0.10) to be improved compared with TD7 pigs. Final BW was similar among pigs fed GD, WD, and PCon (123.1, 122.3, and 125.3 kg, respectively), but pigs fed PCon and GD had greater ( < 0.05) BW than pigs fed NCon (120.0 kg). Throughout the growing-finishing period, BW was similar among TD treatments. The GD FS was more effective than the WD FS in maintaining overall G:F (0.424 and 0.414 +/- 0.005, respectively) and ADG (0.94 and 0.93 +/- 0.03 kg/d, respectively), which were similar ( > 0.05) to those of pigs fed PCon (0.427 +/- 0.005 and 0.96 +/- 0.03 kg/d, respectively). Growth performance of pigs fed GD more closely reflected that of pigs fed PCon than that of pigs fed WD. Delaying the second dose of Improvest from 9 to 5 wk before slaughter resulted in improved growth performance.

ZnBr2-Mediated oxidative spiro-bromocyclization of propiolamide for the synthesis of 3-bromo-1-azaspiro[4.5]deca-3,6,9-triene-2,8-dione.[Pubmed:28379277]

Org Biomol Chem. 2017 Apr 18;15(16):3485-3490.

ZnBr2-Mediated oxidative spiro-bromocyclization of N-arylpropiolamide has been described herein for the synthesis of 3-bromo-1-azaspiro[4.5]deca-3,6,9-triene-2,8-dione with high efficiency. One equivalent of water was introduced into the final product. The reaction efficiently proceeded at room temperature, and an excellent tolerance of functional groups was demonstrated. Under standard conditions, 3-bromo-1-oxaspiro[4.5]deca-3,6,9-triene-2,8-dione and 3-bromo-1-azaspiro[4.5]deca-3,6,9-trien-8-one were synthesized.

Imaging of hypoxia-inducible factor 1alpha and septin 9 interaction by bimolecular fluorescence complementation in live cancer cells.[Pubmed:28380438]

Oncotarget. 2017 May 9;8(19):31830-31841.

Hypoxia-inducible factor 1 (HIF-1) is a major mediator of the hypoxic response involved in tumor progression. We had earlier described the interaction between septin 9 isoform 1 (SEPT9_i1) protein and the oxygen-regulated subunit, HIF-1alpha. SEPT9_i1 is a member of the conserved family of GTP-binding cytoskeleton septins. SEPT9_i1 stabilizes HIF-1alpha and facilitates its cytoplasmic-nuclear translocation. We utilized split yellow fluorescent protein (YFP) bimolecular fluorescence complementation (BiFC) methodology to monitor the interaction between HIF-1alpha and SEPT9_i1 in live cells. N-terminal (YN) and C-terminal (YC) split YFP chimeras with HIF-1alpha and SEPT9_i1 on both their amino and carboxyl termini were generated. HIF-1alpha and SEPT9_i1 chimeras were expressed in cancer cells and screened for functional complementation. SEPT9_i1-YN and YC-HIF-1alpha formed a long-lived highly stable complex upon interaction. The BiFC signal was increased in the presence of hypoxia-mimicking agents. In contrast, YC-DeltaHLH-HIF-1alpha chimera, which lacked the helix-loop-helix domain that is essential for the interaction with SEPT9_i1 as well as the expression of SEPT9_i1 252-379 amino acids fragment required for the interaction with HIF-1alpha, significantly reduced the BiFC signal. The signal was also reduced when cells were treated with 17-N-allylamino-17-demethoxygeldanamycin, an HSP90 inhibitor that inhibits HIF-1alpha. It was increased with fourchlorfenuron, a small molecule that increases the interaction between HIF-1alpha and SEPT9_i1. These results reconfirmed the interaction between HIF-1alpha and SEPT9_i1 that was imaged in live cells. This BiFC system represents a novel approach for studying the real-time interaction between these two proteins and will allow high-throughput drug screening to identity compounds that disrupt this interaction.

Ligand discovery and virtual screening using the program LIDAEUS.[Pubmed:18037921]

Br J Pharmacol. 2008 Mar;153 Suppl 1:S55-67.

This paper discusses advances in docking and scoring approaches with examples from the high-throughput virtual screening program LIDAEUS. We describe the discovery of small molecule inhibitors for the immunophilin CypA, the cyclin-dependent kinase CDK2 and the cyclapolin series of potent Polo-like kinase inhibitors. These results are discussed in the context of advances in massively parallel computing and in the development of annotated databases.

Keywords:

Cyclapolin 9,40533-25-3,Natural Products,Polo-like Kinase, buy Cyclapolin 9 , Cyclapolin 9 supplier , purchase Cyclapolin 9 , Cyclapolin 9 cost , Cyclapolin 9 manufacturer , order Cyclapolin 9 , high purity Cyclapolin 9

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: